Mannatech (MTEX) Competitors $9.10 -0.80 (-8.08%) Closing price 04:00 PM EasternExtended Trading$9.20 +0.10 (+1.09%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTEX vs. INMB, BMEA, INKT, IFRX, DRRX, BRNS, CUE, PYRGF, ICCC, and ANLShould you be buying Mannatech stock or one of its competitors? The main competitors of Mannatech include INmune Bio (INMB), Biomea Fusion (BMEA), MiNK Therapeutics (INKT), InflaRx (IFRX), DURECT (DRRX), Barinthus Biotherapeutics (BRNS), Cue Biopharma (CUE), PyroGenesis Canada (PYRGF), ImmuCell (ICCC), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical products" industry. Mannatech vs. Its Competitors INmune Bio Biomea Fusion MiNK Therapeutics InflaRx DURECT Barinthus Biotherapeutics Cue Biopharma PyroGenesis Canada ImmuCell Adlai Nortye INmune Bio (NASDAQ:INMB) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership. Is INMB or MTEX more profitable? INmune Bio has a net margin of 0.00% compared to Mannatech's net margin of -3.46%. Mannatech's return on equity of -48.60% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets INmune BioN/A -120.62% -92.94% Mannatech -3.46%-48.60%-10.70% Does the media favor INMB or MTEX? In the previous week, INmune Bio and INmune Bio both had 6 articles in the media. INmune Bio's average media sentiment score of 0.58 beat Mannatech's score of -0.01 indicating that INmune Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mannatech 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend INMB or MTEX? INmune Bio presently has a consensus price target of $18.40, suggesting a potential upside of 627.27%. Given INmune Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe INmune Bio is more favorable than Mannatech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57Mannatech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, INMB or MTEX? Mannatech has higher revenue and earnings than INmune Bio. Mannatech is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioINmune Bio$10K6,724.74-$42.08M-$2.48-1.02Mannatech$117.87M0.15$2.49M-$0.10-91.00 Do institutionals & insiders hold more shares of INMB or MTEX? 12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 35.7% of INmune Bio shares are owned by insiders. Comparatively, 41.5% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, INMB or MTEX? INmune Bio has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. SummaryINmune Bio beats Mannatech on 9 of the 16 factors compared between the two stocks. Get Mannatech News Delivered to You Automatically Sign up to receive the latest news and ratings for MTEX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTEX vs. The Competition Export to ExcelMetricMannatechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.82M$2.75B$5.67B$9.83BDividend YieldN/A1.78%3.79%4.08%P/E Ratio-4.4621.8930.5825.12Price / Sales0.15723.29463.91116.12Price / Cash4.64177.1637.4059.05Price / Book2.905.079.096.18Net Income$2.49M$31.61M$3.25B$264.89M7 Day Performance12.35%5.04%4.76%2.66%1 Month Performance11.64%6.25%6.72%3.05%1 Year Performance25.32%12.82%30.51%25.05% Mannatech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTEXMannatech0.4466 of 5 stars$9.10-8.1%N/A+40.2%$18.82M$117.87M-4.46250News CoverageEarnings ReportShort Interest ↑INMBINmune Bio2.1529 of 5 stars$2.86+11.7%$18.40+543.4%-63.6%$60.38M$10K-1.4810Gap UpHigh Trading VolumeBMEABiomea Fusion3.6486 of 5 stars$1.61+2.5%$20.10+1,148.4%-69.0%$58.99MN/A-0.4550INKTMiNK Therapeutics3.1199 of 5 stars$13.22-10.2%$37.50+183.7%+82.4%$58.67MN/A-5.2530News CoverageEarnings ReportAnalyst UpgradeShort Interest ↓Gap UpIFRXInflaRx3.3863 of 5 stars$0.89+3.3%$6.60+642.9%-38.7%$57.74M$180K-1.0860Positive NewsDRRXDURECT1.8421 of 5 stars$1.86+1.4%N/A+42.9%$56.96M$2.03M-12.4080Earnings ReportShort Interest ↓BRNSBarinthus Biotherapeutics2.7048 of 5 stars$1.29-7.9%$6.25+384.5%-4.1%$56.47M$14.97M-0.79107Short Interest ↑CUECue Biopharma4.5053 of 5 stars$0.76+3.4%$4.00+424.9%+27.4%$55.55M$9.29M-1.1460Earnings ReportGap UpPYRGFPyroGenesis CanadaN/A$0.29+2.9%N/A-55.0%$54.55M$9.14M-4.8590ICCCImmuCell0.4008 of 5 stars$6.24+4.0%N/A+90.9%$54.22M$26.49M-89.1370News CoverageEarnings ReportShort Interest ↓ANLAdlai Nortye1.3558 of 5 stars$1.50+3.4%$9.00+500.0%-46.7%$53.51M$5M0.00127Short Interest ↑Gap Up Related Companies and Tools Related Companies INMB Alternatives BMEA Alternatives INKT Alternatives IFRX Alternatives DRRX Alternatives BRNS Alternatives CUE Alternatives PYRGF Alternatives ICCC Alternatives ANL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTEX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mannatech, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Mannatech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access